- Reason for surveillance
- Case definitions
- Notification criteria and procedure
- The diseases
- Managing single notifications
1. Reason for surveillance
To identify cases rapidly in order to control further exposures.
2. Case definition
A probable case requires laboratory suggestive evidence AND clinical evidence.
Laboratory suggestive evidence
- Isolation of a Gram-negative bacillus suggestive of Francisella tularensis where the organism identity and pathogenicity have not yet been confirmed by a reference laboratory, or
- Detection of F. tularensis by nucleic acid testing, or
- Detection of characteristic Gram-negative rods suggestive of F. tularensis, confirmed by a reference laboratory.
A clinically compatible illness.
A confirmed case requires laboratory definitive evidence.
Laboratory definitive evidence
Isolation of F. tularensis.
Factors to be considered in case identification
- Given laboratory confirmation in 2016 of F. tularensis (type B) in ringtail possums in NSW and following threereported cases in humans scratched/bitten by ringtail possums, two confirmed cases in Tasmania and a probable case in New South Wales, presence of the organism in susceptible animals and the environment needs to be considered in further investigations
- Due to the low index of suspicion for tularaemia in Australia by clinicians, and the lack of specialised diagnostic testing techniques such as NAT, direct fluorescent antibody (DFA), and immunohistochemistry tests, diagnosis of early cases is likely to be delayed. Suspicion of local transmission may be triggered by exposure to Australian wildlife in people with no overseas travel history
- Serological testing is not included in the national surveillance case definition, but is considered by the Public Health Laboratory Network to be highly specific and useful in culture-negative cases. A case with a tularaemia-specific IgM or IgG should be highly suspected. Early liaison with the Centre for Infectious Diseases and Microbiology - Public Health (CIDM-PH) at ICPMR, NSW Health Pathology is recommended to discuss relevant further testing and case classification.
- Exposures in suspected cases with a travel history overseas should be considered in light of the epidemiology and known sources of tularaemia transmission in countries visited
- Serendipitious discovery of the organism in the laboratory is another possibility and this is more likely to occur as a result from direct examination of specimens or by culturing the organism. F. tularensis is only occasionally isolated from blood so positive cultures are more likely to result from respiratory specimens
- Handling F. tularensis can represent a biosafety hazard and specialised laboratory safety procedures are required.
Laboratory testing process
CIDM-PH is the only human health laboratory in NSW that can test for F. tularensis. If a case is suspected to have tularaemia or a suspected isolate is cultured from clinical samples by a pathology provider the on-call microbiologist at CIDM-PH should be contacted immediately by the treating physician to determine appropriateness of tests, timelines of testing and specimen transport etc.
3. Notification criteria and procedure
Tularaemia is to be notified to the PHU by laboratories (ideal reporting by telephone on same day as notification).
4. The diseases
The bacterium Francisella tularensis, a Gram-negative rod.
Two types of F. tularensis occur, A and B. Type A is highly virulent in humans and animals and is the most common sub-type in North America. Type B usually produces a mild ulceroglandular infection, is less virulent, and is thought to cause most of the human cases in Europe and Asia. Both A and B types are found in a diverse range of mammals including rodents and rabbits, and can also be isolated from contaminated water, soil and vegetation.
To date, only Type B (F. tularensis subspecies holarctica) has been isolated from common ringtail possums (Pseudocheirus peregrinus) in NSW. There have been four reported cases of human transmission in Australia. Three occurred after scratches/bites by possums, two confirmed cases of Type B infection in Tasmania in 2011 linked to a ringtail possum and unidentified possum respectively, and a probable case in NSW in 2020 to a ringtail possum. The fourth case, also defined as probable, was likely exposed during necropsy of Australian wildlife, of which the infected animal has not been clearly identified but which was not a possum species.These are the first records of F. tularensis in Australia and the southern hemisphere. In countries where tularaemia is endemic, Type B is also associated with streams, ponds, lakes, rivers and from diseased semi-aquatic animals such as beavers and muskrats, and infected blood feeding arthropods including ticks.
Of the possible agents that could be used in a bioterrorist attack, F. tularensis is included in the high risk category (Tier 2 security sensitive biological agent under the National Health Security Act 2007).
Mode of transmission
The bacteria can enter the body through the skin, eyes, mouth, throat or lungs. Infection can be acquired by:
- skin contact with sick or dead infected animals, including bites/scratches
- bites of infected blood-feeding arthropods, such as ticks and deer fly
- drinking contaminated water or eating undercooked meat of an infected animal
- laboratory exposure
- inhalation of contaminated dusts or aerosols.
- Bite/scratch from infected ringtail possums should be considered suspicious
- Transmission from other native Australian mammals or insects through bites/scratches, or in a laboratory setting, cannot be excluded.
F. tularensis is listed by the Centers for Disease Control as a potential agent for bioterrorism.
It is not spread from person to person.
The incubation period for tularemia ranges from 1-14 days, but is usually 3-5 days. F. tularensis bacteria are hardy, and can survive weeks to months in the environment.
Clinical Presentation and Course
Tularaemia can manifest as one or more clinical syndromes. The syndrome depends on the route of transmission, the size of the inoculum, and the virulence of the infecting strain. However, most cases are characterised by a rapid onset of headache, chills, nausea, vomiting, high fever, lymphadenopathy and prostration.
Illness usually falls into one of the following categories:
- Ulceroglandular: (80% of cases) this is the most common type and follows inoculation via a skin lesion. Patients present with a primary local ulcerative lesion and tender, regional lymphadenopathy. Systemic symptoms are prominent
- Pneumonic (pulmonary): occurs as a primary infection following inhalation of organisms, and in 10-15% of those with ulceroglandular tularaemia and 50% of those with typhoidal tularaemia. The presenting symptoms are those of atypical pneumonia. This form is the most probable one in the event of a bioterrorist attack. Untreated, it has a 30-60% mortality rate
- Typhoidal: (10% of cases) a severe form of tularaemia, with prominent systemic and gastrointestinal symptoms. Half the cases will develop pneumonic tularaemia
- Oculoglandular: (1% of cases) a combination of painful conjunctivitis (usually unilateral) with local lymphadenopathy. Follows inoculation via the conjunctiva
- Glandular: similar to ulceroglandular form but without skin lesions
- Oropharyngeal: a rare form that occurs after ingestion of organisms. The patient develops stomatitis or pharangitis accompanied by regional lymphadenopathy.
5. Managing single notifications
On the same day as notification of a probable or confirmed case, begin the investigation and telephone the Communicable Diseases Branch (CDB).
In the situation of a suspected deliberate exposure contact CDB immediately.
Within 1 working day of notification, enter probable and confirmed cases on NCIMS.
Given the isolation of F. tularensis in ringtail possums for the first time in Australia in 2016, and the probable case in NSW in 2020 linked to an unidentified Australian wildlife source (that was not a possum), early response to a notification is required to better understand the epidemiology of tularaemia in Australia.
The response to a notification will normally be carried out in collaboration with the case's health carers, but regardless of who does the follow-up, PHU staff should ensure that action has been taken to:
- confirm the onset date and symptoms of the illness
- confirm results of relevant pathology tests, or recommend the tests be done
- determine if the case or relevant care-giver has been informed of the diagnosis is before beginning the interview
- seek the doctor's permission to contact the case or relevant care-giver
- determine the likely source of infection, such as a laboratory that handles infectious specimens, local exposures or exposure overseas
- if found to be locally acquired, coordination with the Department of Primary Industries for further wildlife or environmental assessments of causal agent will be coordinated by CDB.
Investigation and treatment
See the latest edition of the Therapeutic Guidelines: Antibiotic.
The case or relevant care-giver should be informed about the nature of the infection and the mode of transmission.
Obtain a history of overseas and domestic travel as well as possible exposures to wild or domestic animals (including common ringtail possums and other Australian wildlife), farms, recent tick bites, contact with or drinking water from natural sources including lakes, rivers, streams and ponds, and eating wild game or potentially contaminated imported products, in the two weeks prior to symptom onset.
Isolation and restriction
In the case of local acquisition, environmental evaluation would be recommended in conjunction with officials from NSW Department of Primary Industries, who may need to initiate animal control measures.
Identification of contacts
Contacts are those who may have been exposed to the same source as the case. If the infection was acquired overseas, communication with the relevant communicable diseases authorities in the country of acquisition would normally be carried out by CDB in collaboration with the Australian Government Department of Health.
For further information please call your local Public Health Unit on 1300 066 055